menu
    • menu
    [{"orgOrder":0,"company":"Sucampo Pharmaceuticals","sponsor":"Mallinckrodt Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"IRELAND","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Lubiprostone","moa":"Chloride channel protein 2","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Sucampo Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sucampo Pharmaceuticals \/ Sucampo Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"Sucampo Pharmaceuticals \/ Sucampo Pharmaceuticals"},{"orgOrder":0,"company":"Sucampo Pharmaceuticals","sponsor":"Mallinckrodt Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"IRELAND","productType":"Plant Extract\/Herbal","year":"2011","type":"Inapplicable","leadProduct":"Isopropyl Unoprostone","moa":"prostaglandins","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Sucampo Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Sucampo Pharmaceuticals \/ Sucampo Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Sucampo Pharmaceuticals \/ Sucampo Pharmaceuticals"}]

    Find Clinical Drug Pipeline Developments & Deals by Sucampo Pharmaceuticals

    Menu

    Sucampo Pharmaceuticals

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    INSPECTIONS & REGISTRATIONS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Sucampo Pharmaceuticals

                            U.S.A arrow
                            OTS 2025
                            Not Confirmed

                            Sucampo Pharmaceuticals

                            U.S.A arrow
                            OTS 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Isopropyl Unoprostone

                            Therapeutic Area : Ophthalmology

                            Study Phase : Phase II

                            Recipient : Mallinckrodt Pharmaceuticals

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Study to Evaluate the Ocular Blood Flow Effects of Unoprostone Isopropyl in Adults With Dry Age-related Macu...

                            Details : Unoprostone Isopropyl is a Plant Extract/Herbal drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Macular Degeneration.

                            Product Name : Undisclosed

                            Product Type : Plant Extract/Herbal

                            Upfront Cash : Inapplicable

                            June 23, 2011

                            Lead Product(s) : Isopropyl Unoprostone

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Phase II

                            Recipient : Mallinckrodt Pharmaceuticals

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Sucampo Pharmaceuticals

                            U.S.A arrow
                            OTS 2025
                            Not Confirmed

                            Sucampo Pharmaceuticals

                            U.S.A arrow
                            OTS 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Lubiprostone

                            Therapeutic Area : Gastroenterology

                            Study Phase : Phase III

                            Recipient : Mallinckrodt Pharmaceuticals

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Opioid-induced Bowel Dysfunction (OBD) Pivotal Assessment of Lubiprostone (OPAL)

                            Details : Lubiprostone is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Opioid-Induced Constipation.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            February 17, 2011

                            Lead Product(s) : Lubiprostone

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : Phase III

                            Recipient : Mallinckrodt Pharmaceuticals

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth